Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Clinical, virological and immunological evolution of the olfactory and gustatory dysfunction in COVID-19

Eugenia Maiorano\textsuperscript{a}, Anna Calastri\textsuperscript{a}, Carlo Robotti\textsuperscript{a,b,*}, Irene Cassaniti\textsuperscript{c}, Fausto Baldanti\textsuperscript{b,c}, Valentina Zuccaro\textsuperscript{d}, Edoardo Stellin\textsuperscript{e}, Virginia V. Ferretti\textsuperscript{f}, Catherine Klersy\textsuperscript{f}, Marco Benazzo\textsuperscript{a,b}

\textsuperscript{a} Department of Otorhinolaryngology – Head and Neck Surgery, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
\textsuperscript{b} Department of Clinical, Surgical, Diagnostic and Pediatric Sciences, University of Pavia, Pavia, Italy
\textsuperscript{c} Molecular Virology Unit, Microbiology and Virology Department, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
\textsuperscript{d} Infectious Diseases Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy
\textsuperscript{e} Department of Otorhinolaryngology, ASST Valle Olona, Busto Arsizio, Italy
\textsuperscript{f} Clinical Epidemiology and Biometry Unit, Fondazione IRCCS Policlinico San Matteo, Pavia, Italy

ARTICLE INFO

Keywords:
COVID-19
Smell
Taste
Immunoglobulins
RNA
Viral load

ABSTRACT

Purpose: New-onset olfactory and gustatory dysfunction (OGD) represents a well-acknowledged COVID-19 red flag. Nevertheless, its clinical, virological and serological features are still a matter of debate.

Materials and methods: For this cohort study, 170 consecutive subjects with new-onset OGD were consecutively recruited. Otolaryngological examination, OGD subjective grading, nasopharyngeal swabs (NS) for SARS-CoV-2 RNA detection and serum samples (SS) collection for SARS-CoV-2 IgG quantification were conducted at baseline and after one (T1), two (T2) and four weeks (T3).

Results: SARS-CoV-2 infection was confirmed in 79% of patients. Specifically, 43% of positive patients were detected only by SS analysis. The OGD was the only clinical complaint in 10% of cases. Concurrent sinonasal symptoms were reported by 45% of patients. Subjective improvement at T3 was reported by 97% of patients, with 40% recovering completely. Hormonal disorders and RNA detectability in NS were the only variables associated with OGD severity. Recovery rate was higher in case of seasonal influenza vaccination, lower in patients with systemic involvement and severe OGD. Not RNA levels nor IgG titters were correlated with recovery.

Conclusion: Clinical, virological and serological features of COVID-19 related OGD were monitored longitudinally, offering valuable hints for future research on the relationship between host characteristics and chemosensory dysfunctions.

1. Introduction

Coronavirus disease 2019 (COVID-19), caused by Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2), has been officially recognized as a pandemic by the World Health Organization (WHO), reaching at the time of writing (June 2021) more than 200 countries, with almost 178 million confirmed cases and more than 3 million deaths [1]. Besides nonspecific presenting symptoms, the olfactory and gustatory dysfunction (OGD) soon appeared to be one of the main features at onset, especially in paucisymptomatic cases and early phases of the disease [2–4]. The concomitance of OGD and viral infections is indeed a frequent finding [5], especially in otolaryngology, with OGD typically arising with nasal obstruction and discharge. Nevertheless, OGD in COVID-19 patients is weakly correlated with sinonasal symptoms. Moreover, it typically shows sudden and early onset, being often the only reported symptom [6–9].

The prevalence of SARS-CoV-2 infection in new-onset OGD patients is well acknowledged, although it differs significantly between studies (74–94%) [10–13]. Nevertheless, little is known about its connection with epidemiological variables and comorbidities. Furthermore, only few studies investigated the correlation between viral load on one side and the features of the chemosensitive dysfunction on the other, not taking into consideration serological parameters. Finally, to the best of our knowledge, no cross-sectional or prospective studies have been
conducted to date employing both serology and molecular assays to better define the prevalence of SARS-CoV-2 infection in new-onset OGD.

The present study was therefore designed in order to longitudinally assess the prevalence of SARS-CoV-2 infection in new-onset OGD patients, basing on molecular and serological quantitative assays. In addition, OGD characteristics such as baseline severity, resolution rate and timing were investigated, correlating specific severity and resolution patterns to relevant clinical, virological and immunological features.

2. Materials and methods

The present observational cohort study was conducted at the Otolaryngology Department of Fondazione IRCCS Policlinico San Matteo (Pavia, Italy), after being approved by the internal review board (reference number: 20200041154). To ensure high quality presentation, the Strengthening the Reporting of Observational studies in Epidemiology guidelines were followed [14]. The study was conducted according to the World Medical Association Declaration of Helsinki.

2.1. Study population

Patients referred to our Department between March and May 2020 for new-onset OGD were consecutively recruited. Written informed consent was obtained from all participants. Inclusion criteria were as follows: age of 18 years or above; new-onset OGD. Exclusion criteria included: preexisting chronic OGD; chronic sinonasal pathologies; nasal decongestant abuse; substance abuse; neuropsychiatric disorders; major comorbidities.

2.2. Molecular and serological testing for SARS-CoV-2

Nasopharyngeal swabs (NS) and serum samples (SS) were prospectively collected from all patients at T0 and after one (T1), two (T2) and four (T3) weeks. Detection and quantification of SARS-CoV-2 RNA were performed on samples collected from the rhinopharynx (FLOQSwabs™, Copan Italia, Brescia, Italy). RNA was extracted from 400 μL of Universal Transport Medium (UTM™) using the QIAsymphony® DSP Virus/Pathogen Midi Kit (Complex 400 protocol), according to the manufacturer’s instructions (QIAGEN, Qiagen, Hilden, Germany). Moreover, specific real-time RT-PCRs targeting RNA-dependent RNA polymerase and E genes were employed to detect the presence of SARS-CoV-2 according to the WHO guidelines’ and Cor- man’s protocol [17]. Sequential SS were examined using chemiluminescent assay (Liason SARS-CoV-2 S1/S2 IgG, Diasorin, Saluggia, Italy) for quantitative characterization of SARS-CoV-2 anti-S1 and anti-S2 IgG antibodies. Results were given as AU/mL, and a cut-off of 15 AU/mL was set to define positive samples.

2.3. Olfactory and gustatory dysfunction (OGD)

At all times, a dedicated form was administered to investigate OGD features: type (“hyposmia/hypongeusia” versus “anosmia/ageusia”), date and type of onset (“sudden” versus “gradual”), course (“constant” versus “fluctuating”), general signs and symptoms (GSS), nasal symptoms (nasal obstruction, rhinorrhea). Since psychophysical tests were not practicable within COVID-19 emergency state, OGD subjective grading was conducted at all times through dedicated measures. First, a 100-millimeter Visual Analogue Scale (VAS), anchored at each end with verbal descriptors (“no impairment-0” and “extreme impairment-100”), was administered to investigate both gustatory (VAS-G) and olfactory (VAS-O) dysfunctions. The VAS has been already employed for OGD assessment. Moreover, significant correlations have been demonstrated between this scale and the Objective Odor Stick Tests (OOST) [18–21].

Two additional patient-reported outcome (PRO) instruments were also administered: the Hyposmia Rating Scale (HRS) and the Chemosensory Complaint Score (CCS). The HRS was originally developed to grade olfactory dysfunctions in Parkinson’s disease [22]. Each of the six items (scent of flowers; unburnt gas; garbage, sewage or other foul smelling materials; scent of perfume; smell of stuffiness or strong body odor; smell of home cooking) is rated on a five-point Likert scale from 1 (“always aware of the smell”) to 5 (“unfamiliar with or never smell the smell”), with a total score ranging from 6 (no impairment) to 30 (worst impairment). Its clinical utility has been tested in several settings [22–24], demonstrating a strong correlation with the OOST. Taste impairments were graded instead using the CCS [25], originally developed to grade taste alterations in HIV patients and subsequently tested in chronic rhinosinusitis [26], which provides the best approximation of a patient-reported taste metrics. The CCS is an eight-item questionnaire investigating multiple features of taste dysfunctions: change in the sense of taste, change in the way food tastes, presence and quality of a bad taste, effect of medications on taste and changes in quality of four taste subgroups (salt, sweet, sour and bitter). Each of the items is given one point if abnormal. A ninth question deals with the overall severity of the dysfunction; it is given one point in case of a mild or moderate dysfunction or two points for a severe dysfunction. Thus, its total score ranges from 0 (no complaints) to 10 (severe complaints).

Given the context of the present pandemic, no validation studies of these PRO instruments were conducted. However, both the HRS and the CCS were preliminarily translated into Italian by two senior otolaryngologists and one bilingual translator to retain the meaning of the original items.

2.4. Statistical analysis

Qualitative variables were described as absolute frequencies and percentages. Quantitative variables were summarized in terms of median and interquartile range (IQR). Levels of the scales at T0 were compared according to epidemiological and clinical features using Mann-Whitney test or Kruskall-Wallis test (depending on whether the comparison was between two or more independent groups of patients). Scales trends during follow-up were evaluated by linear regression models. Standard errors were estimated with a clustered sandwich estimator in order to allow for intra-group correlation. Similarly, linear
regression models with clustered sandwich standard errors were used to evaluate scales trends during follow-up as RNA copies/mL and IgG titers. Complete recovery free survival was calculated as the time between the enrollment and date of recovery or last follow-up. The crude effect (univariable analysis) of clinical and epidemiological features at T0 on complete recovery free survival was estimated by Cox Proportional Hazard models. Variables with a p-value lower than 0.2 in univariable analysis were candidate to enter in multivariable model. p values < 0.05 were considered statistically significant. All statistical analyses were conducted using the version 16 of the software Stata (StataCorp 2019; Stata Statistical Software: Release 16; College Station, TX: StataCorp LLC).

3. Results

3.1. Study population

Overall, 170 new-onset OGD patients were enrolled: 162 patients completed the follow-up (T3), while 3 and 2 patients were lost at T1 and T2, respectively. The median time from OGD onset to enrollment was 11 days (IQR 6–19). Table 1 summarizes demographic and clinical features of the participants. None of them had pathological findings at the ENT evaluation.

3.2. Molecular and serological testing for SARS-CoV-2

SARS-CoV-2 seroprevalence (SARS-CoV-2 IgG levels) and SARS-CoV-2 RNA copies in NS were evaluated over time (Fig. 1). Globally, SARS-CoV-2 infection was confirmed through NS and/or SS in 134 patients (79%; 95% CI: 72%–85%). SS analysis alone detected only 55 COVID-19 patients (43.3%).

3.3. Olfactory and gustatory dysfunction (OGD)

Clinical features of SARS-CoV-2 patients are depicted in Table 2. The OGD demonstrated sudden onset and constant intensity in most cases. Almost all patients (128; 96%) had a combined perceptual disorder. Seventy-four patients (55%) reported no additional sinonasal symptoms. When associated with nasal obstruction, the OGD occurred at the same time in 19 patients (44%), while it manifested before (median 2 days IQR 3–8) in 9 (21%) and 15 (35%) patients, respectively. Interestingly, an OGD with or without sinonasal symptoms was the only clinical complaint in 14 cases (11%). With regards to GSS, they occurred simultaneously with the OGD in 27 patients (25%), while they preceded (median 4 days IQR 2–7) or followed (median 5 days IQR 2–8) the OGD in 71 (65%) and in 11 (10%) subjects, respectively. No patients had severe COVID-19 symptoms requiring hospitalization during follow-up.

OGD severity, although fluctuant in 15 patients (11%), showed an overall improving trend. In fact, both the baseline HRS score of 29 (IQR 27–30) and the baseline CCS score of 7 (IQR 5–8) significantly improved to 12 (IQR 6–22) and 0 (IQR 0–3) at T3, respectively (p < 0.001). Similarly, baseline VAS-O and VAS-G decreased from 9 (IQR 8–10) and 8 (IQR 5–10) to 2 (IQR 0–5) and 1 (IQR 0–4), respectively (p < 0.001). At the univariable analysis, endocrine disorders and positive NS were the only variables significantly correlated with OGD severity (Table 3). Precisely, in case of endocrine disorders or positive NS, patients reported higher subjective impairments. SARS-CoV-2 RNA levels in NS as well as IgG titers showed no significant correlation with OGD severity, not at baseline nor during follow-up (Table 4).

As far as recovery is concerned, 130 patients (97%) reported an improvement of the OGD at T3, but only 53 (40%) recovered completely within 23 days from onset (IQR 18–32). Specifically, higher severity at onset and GSS were associated with a lower probability of complete recovery within T3 (Table 5). A mild association between influenza vaccination and complete OGD recovery was also demonstrated through the multivariable analysis (Table 6). No other relevant associations have
Table 3
Association between epidemiological and clinical features and the olfactory and gustatory dysfunction severity at T0.

| Variable                  | VAS-O       | VAS-G       | HRS         | CCS         |
|---------------------------|-------------|-------------|-------------|-------------|
|                           | Median (IQR) | Median (IQR)| Median (IQR)| Median (IQR) |
| Sex                       |             |             |             |             |
| Female                    | 0.5 (0–3)   | 0.769       | 2 (0–5)     | 0.789       |
| Male                      | 1 (0–2)     | 2 (0–4.5)   | 29 (26–30)  | 29 (26–30)  |
| Age (years)               |             |             |             |             |
| <45                       | 0 (0–3)     | 0.246       | 2 (0–5)     | 0.654       |
| ≥45                       | 1 (0–2)     | 2 (1–4)     | 29 (27–30)  | 30 (26–30)  |
| Smoking                   |             |             |             |             |
| Ex                        | 1 (0–3)     | 0.673       | 28 (27–30)  | 30 (25–30)  |
| No                        | 0 (0–2)     | 1 (0–3)     | 29 (26–30)  | 29 (26–30)  |
| Influenza vaccination     |             |             |             |             |
| Ex                        | 1 (0–2)     | 0.475       | 30 (27–30)  | 30 (27–30)  |
| No                        | 0 (0–2.5)   | 2 (0.5–3)   | 30 (27–30)  | 30 (27–30)  |
| Allergies                 |             |             |             |             |
| No                        | 1 (0–3)     | 0.234       | 30 (29–30)  | 30 (29–30)  |
| Hormonal disorders        |             |             |             |             |
| Yes                       | 0 (0–1)     | 0.134       | 30 (28–30)  | 30 (28–30)  |
| General symptoms          |             |             |             |             |
| Yes                       | 0 (0–2)     | 0.389       | 29 (26–30)  | 29 (26–30)  |
| Nasal obstruction         |             |             |             |             |
| Yes                       | 0 (0–2)     | 2 (0–4)     | 29 (27–30)  | 29 (27–30)  |
| Sudden onset              |             |             |             |             |
| Yes                       | 1 (0–3)     | 0.146       | 28 (25–30)  | 28 (25–30)  |
| Concurrent pathologies    |             |             |             |             |
| Yes                       | 0 (0–2)     | 0.920       | 29 (27–30)  | 29 (27–30)  |
| SARS-CoV-2 RNA (NS)       |             |             |             |             |
| POS                       | 0 (0–2)     | 0.001*      | 30 (28–30)  | 30 (28–30)  |
| VAS-O, Visual Analogue Scale – Olfactory; VAS-G, Visual Analogue Scale – Gustatory; HRS, Hyposmia Rating Scale; CCS, Chemosensory Complaint Score. |

Table 4
Correlations between log_{10} SARS-CoV-2 RNA copies/mL, SARS-CoV-2 IgG titers and OGD severity at baseline and during follow-up.

| Log_{10} RNA copies/mL | IgG titer | T0 Follow-up | T0 Follow-up |
|------------------------|-----------|--------------|--------------|
| Log_{10} RNA copies/mL |           |              |              |
| VAS-O                  |           |              |              |
| R = -0.05, p = 0.690   | Corr = 0.11, r = 0.841 |              |              |
| VAS-G                  | R = -0.05, p = 0.657 | Corr = 0.76, r = 0.435 |              |              |
| HRS                    | R = -0.07, p = 0.558 | Corr = 0.9, r = 0.945 |              |              |
| CCS                    | R = -0.01, p = 0.974 | Corr = -0.5, r = -0.05 |              |              |
| VAS-O, Visual Analogue Scale – Olfactory; VAS-G, Visual Analogue Scale – Gustatory; HRS, Hyposmia Rating Scale; CCS, Chemosensory Complaint Score. |

been highlighted. SARS-CoV-2 RNA detectability in NS and SARS-CoV-2 IgG positivity in SS were not associated with OGD recovery rate (p = 0.523 and p = 0.214, respectively).

4. Discussion
This study aimed to investigate the clinical, virological and immunological features of the COVID-19-related OGD over time. Several studies demonstrated that the OGD is a strong clinical marker of COVID-19, with a positive predictive value of 61% [7], even though its relevant specificity (93–99%) is not matched by an equally high sensitivity (23–43%) [6]. In our investigation, the OGD confirmed its clinical relevance, being the only reported complaint in 10.5% of positive patients. The chemosensory impairment demonstrated fundamental importance for diagnosis even in case of systemic disease, since in 10.1% of patients the OGD anticipated GSS by 5 days (IQR 2–8).

The overall prevalence of SARS-CoV-2 infection, based on NS and SS analyses combined, was 79%. Most studies investigating SARS-CoV-2 prevalence in OGD patients relied on NS results; one, like the reports from Lechien (88%) [10], Salmon-Ceron (94%) [11] and Hopkins (74%) [27]. Only two studies so far employ SS testing, specifically a preliminary report from our study group (75%) [9] and a cross-sectional study employing solely qualitative point-of-care serological kits (77.6%) [28]. To the best of our knowledge, this is the first study assessing SARS-CoV-2 prevalence relying on both NS and SS within a controlled clinical setting. Noteworthy, our results highlighted the cruciality of serological testing for COVID-19 diagnosis in OGD patients. In fact, more than 40% of COVID-19 cases were detected only by means of serological essays, implying that NS or SS alone could have underestimated SARS-CoV-2 prevalence. This may be primarily related to the interval between symptoms' onset and laboratory confirmation. Indeed, as we previously observed in a smaller cohort [9], the great majority of patients developed SARS-CoV-2 IgG three weeks after symptoms' onset, while RNA detectability in NS gradually decreased over time (Fig. 1).

As far as clinical features are concerned, literature reveals how COVID-19-related OGD usually presents as a combined disorder,
impairments in COVID-19 [43]. A more severe SARS-CoV-2 infection and, therefore, reduced abilities of association between OGD and GSS has never been deeply investigated to confirmed by other studies investigating the evolution of chemosensory relevant variable influencing complete resolution. This evidence is clinical and experimental research, which should be aimed at better bulb [50]. These findings and our results offer interesting hints for future

disorders on smell and taste is well-acknowledged [34], since the
olfactory and the endocrine system are intimately linked. Axonal pro-
tections to and from the olfactory bulb allow a crosstalk between the
olfactory system and the hypothalamus. Moreover, the olfactory muco-
sa and bulb cells express receptors and peptides involved in metabolic
homeostasis [37].

Despite the overall improving trend, only 40% of patients recovered completely from the OGD at T3. Resolution rate appear to be variable in literature, ranging from 13% [39] to 86% [40], mainly depending on follow-up duration and OGD evaluation methodology (quantitative vs qualitative) [41,42]. In our sample, severity at onset was the most relevant variable influencing complete resolution. This evidence is confirmed by other studies investigating the evolution of chemosensory impairments in COVID-19 [43–47]. To the best of our knowledge, the association between OGD and GSS has never been deeply investigated to date. In our study, GSS were associated with lower chances of complete recovery. It might be speculated that systemic involvement could reflect a more severe SARS-CoV-2 infection and, therefore, reduced abilities of the body to cope with the infection. Interestingly, Lovato et al. [48], in their preliminary report on 121 COVID-19 patients, found out that among GSS, the absence of fever was significantly associated with persistent OTD. Authors speculate that, since fever is associated with severe COVID-19, patients with OGD without fever would experience a mild–moderate COVID-19. However, to date no final inferences can be drawn in this matter, and further studies are needed to properly test this hypothesis.

Impressively, a significant association between influenza vaccination and complete recovery at T3 was also verified. Similar trends were also noted before the present pandemic by Flanagan, who highlighted how influenza vaccination rates were significantly lower among older OGD patients [49]. Furthermore, this association was also explored on murine models, in which intranasal immunization demonstrated attenuation properties on both viral localization and inflammation of the olfactory bulb [50]. These findings and our results offer interesting hints for future clinical and experimental research, which should be aimed at better understanding the connection between acquired immunity and chemosensory dysfunctions.

Several virological and immunological features of COVID-19 OGD appearing noteworthy. First, the only significant virological correlation was found between RNA detectability in NS on one side and OGD baseline severity on the other. Surprisingly, while the presence of SARS-CoV-2 in the nasopharynx was associated with higher perceptual impairments, RNA copies/mL never showed significant correlations with OGD severity. These findings suggest that active SARS-CoV-2 infections might be the only prerequisite for the development of perceptual impairments, not necessarily requiring higher viral loads to reach clinical relevance. The relationship between the viral load and the chemosensory dysfunction is still a matter of debate. Jain et al., comparing the cycle threshold (CT) value on PCR assay in COVID-19 patients with and without OGD, found that patients with olfactory dysfunction had higher viral load than those without perceptual impairment [51]. However, Vaira et al. and Cho et al. did not find a significant correlation between the CT value and the olfactory function, suggesting that the OGD severity might be related to individual susceptibility rather than viral load [52,53]. Further studies investigating the correlation of viral load and the chemosensory dysfunction COVID-19 related are needed.

With regards to immunological data, no significant associations were found between IgG titers and overall OGD severity or trend. These results appear to be quite unexpected, as higher IgG titers should correspond to more effective responses to the infection and, theoretically, less severe and less lasting symptoms. Nevertheless, also this serological evidence needs further investigation.

Sinonasal symptoms other than the chemosensory impairment itself (i.e., nasal obstruction and nasal discharge) affected less than half of positive OGD patients. However, Naeini and colleagues demonstrated through computed tomography of parasanal sinuses that there were no significant pathological changes in the olfactory clefts and sinonasal mucosa in the 49 anosmic COVID-19 patients analyzed [54].

Furthermore, no significant differences in terms of OGD baseline severity, course and resolution were found between patients with and without nasal complaints. Notoriously, sinonasal symptoms alone may lead to olfactory dysfunctions, since nasal inflammation and mucosal swelling can prevent olfactory molecules from reaching the olfactory clefts. The persistence of olfactory impairments without major nasal complaints and after the acute phase of COVID-19 strengthens the hypothesis of a direct damage of both the olfactory epithelium and central olfactory pathways. SARS-CoV-2 is a neurotropic virus, able to spread from the peripheral olfactory system to the central nervous system [55–57]. Several reports have demonstrated viral spreading towards the olfactory bulb through the olfactory neuroepithelium [10,58,59]. ACE-2 and TMPRSS2, required for SARS-CoV-2 entry in host cells, were detected in sustentacular and olfactory stem cells in human specimens [60,61]. Central nervous system involvement by SARS-CoV-2 has been proven even radiologically, with MRI evidence of olfactory bulb abnormalities in anosmic COVID-19 patients [62,63]. Moreover, SARS-CoV-2 particles, diffuse infiltration of CD163-positive macrophages and cytotoxic T lymphocytes have been identified in the olfactory bulbs of patients with severe COVID-19 [64]. Moreover, there is emerging evidence regarding the role of SARS-CoV-2 in determining olfactory impairment through blocking the rapid turnover of the olfactory receptors. In fact, according to recent studies, SARS-CoV-2 might attack the nasal serous gland inhibiting the production of the growth factors necessary for stem cells activation and transformation in olfactory receptors [65]. In conclusion, the contribution of different potential pathogeneses to the olfactory impairment of COVID-19 deserves further studies.

This study has several limitations. Firstly, due to the COVID-19 emergency state, the OGD was not evaluated with psychophysical tests or electrophysiological studies, since they were not practicable. These instruments could be potentially employed to screen residual long-lasting OGD after the resolution of the emergency state. Secondly, although a thirty-day follow-up is significantly longer than the average follow-up of previous reports, longer monitoring could have better contributed in evaluating the rate of persistent OGD. Lastly, in reason of

---

**Table 6**

Multivariable analysis of epidemiological and clinical variables related to OGD resolution at the end of the follow-up period (T3).

|                      | Model 1 (HRS) | Model 2 (CCS) |
|----------------------|--------------|--------------|
|                      | HR 95% CI    | p            |
|                      | HR 95% CI    | p            |
| Age (years)          | 0.99 0.97–1.01 0.361 | 0.99 0.96–1.01 0.232 |
| Seasonal influenza vaccination (yes vs no) | 2.33 1.10–4.95 0.027 | 2.42 1.14–5.14 0.021 |
| General sign symptoms (yes vs no) | 0.54 0.29–1.01 0.053 | 0.54 0.29–1.00 0.051 |
| HRS                  | 0.93 0.88–0.98 0.009 | – – – – – – – |
| CCS                  | – – – – – – – – | 0.86 0.79–0.94 0.001 |

HR, Hazard Ratio; CI, Confidence Interval; HRS, Hyposmia Rating Scale; CCS, Chemosensory Complaint Score.
the current emergency, OGD etiologies in SARS-CoV-2 negative patients were not investigated.

5. Conclusion

The present longitudinal study depicts the clinical course of COVID-19-related OGD with regards to its virological and immunological features. Specifically, the combination of SS and NS appeared to be crucial in order to identify a higher rate of positive COVID-19 patients suffering from OGD. A higher OGD severity was reported in case of RNA detectability in NS and concurrent endocrine disorders. Recovery rates were lower in case of higher severity at onset, as well as in case of systemic symptoms. Contrariwise, a higher recovery rate was highlighted for subjects who underwent influenza vaccination, offering hints for future research investigating the relationship between acquired immunity and chemosensory dysfunctions.

Previous presentations

The manuscript was not previously presented.

Funding source

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

CRediT authorship contribution statement

EM: patient enrollment, patient examination and testing, questionnaire administration, literature revision, drafting of the manuscript; AC: patient enrollment, patient examination and testing, questionnaire administration, literature revision; CR: literature revision, drafting of the manuscript.

Declaration of competing interest

None.

Acknowledgements

We would like to thank all participants enrolled in the present study. This paper is dedicated to all healthcare workers fighting against COVID-19.

References

[1] World Health Organization. Coronavirus disease (COVID-19) pandemic. http://www.who.int/emergencies/diseases/novel-coronavirus-2019. [Accessed 20 June 2020].
[2] Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet 2020;395(10223):497–506.
[3] Giacomelli A, Pezzati L, Conti F, et al. Self-reported olfactory and taste disorders in subjects who underwent influenza vaccination, offering hints for future observational studies in epidemiology (STROBE) statement: guidelines for reporting observational studies. J Clin Epidemiol 2008;61(4):344–9.
[4] Rocke J, Parmel SJ, Marsh JJ, McWhorter AJ, Friedlander PL. Risk of SARS-CoV-2 transmission during flexible laryngoscopy: a systematic review. JAMA Otolaryngol Head Neck Surg 2020;146(9):851–6.
[5] Makaronidis J, Mok J, Balogun N, Magee CG, Omar RZ, Carnemolla A, Othieno F, Schlosser RJ, Rowan NR, et al. Taste impairment in chronic rhinosinusitis. Int Forum Allergy Rhinol 2018;8(7):783–9.
[6] Raad RA, Ganti A, Gohtabshi K, Lehrich BM, Papagianopoulos P, LoSavio P, Mahdavinia M, Kuan EC, Batra PS, Tajbadeen BA. Temporal patterns of nasal symptoms in patients with mild severity SARS-CoV-2 infection. Am J Otolaryngol 2021 Apr 24;42(6):103068. https://doi.org/10.1016/j.amjoto.2021.103068.
[7] Swidzinski T, Linkowska-Swidszina K, Czerwiec-Wolska H, et al. Hypothyroidism affects olfactory evoked potentials. Biomed Res Int 2016:9583495. https://doi.org/10.1155/2016/9583495.
[8] Deniz F, Ay SA, Salihoglu M, et al. Thyroid hormone replacement therapy improves olfaction and taste sensitivity in primary hypothyroid patients: a prospective randomized clinical trial. Exp Clin Endocrinol Diabetes 2016;124(6):562–7.
[9] McConnell RJ, Menendez CE, Smith FR, Herkin RJ, Rivlin RS. Defects of taste and smell in patients with hypothyroidism. Am J Med 1975;59(3):354–64.
[10] Anto Pajari, L. NozAGICS, M–C, Aims P, et al. Olfaction under metabolic influences. Chem Senses 2012;37:769–79.
[11] Hummel T, Whitcroft KL, Andrews P, et al. Position paper on olfactory dysfunction. Rhinology 2020;277(8):2251–61.
[12] Seden N, Yigit E, Yigit O, Kaygiz A. Subjective olfaction ratings in patients with and without olfactory disorders. J Laryngol Otol 2012;126(7):692–7.
[13] Mercante G, Ferreli F, De Virgilio A, et al. Prevalence of taste and smell dysfunction among patients treated with chemo-radiotherapy. J Laryngol Otol 2016;130(5):453–61.
[14] Yu Q, Guo P, Li D, et al. Olfactory dysfunction and its relationship with clinical symptoms of Alzheimer disease. Aging Dis 2018;9(6):1084–95.
[15] Heald AE, Pieper CF, Schiffman SS. Taste and smell complaints in HIV-infected patients. AIDS 1998;12(13):1667–74.
[16] Othieno F, Schlosser RJ, Rowan NR, et al. Taste impairment in chronic rhinosinusitis. Int Forum Allergy Rhinol 2018;8(7):783–9.
[17] Makaronidis J, Mok J, Balogun N, Magee CG, Omar RZ, Carnemolla A, Batterham RL. Seroreprevence of SARS-CoV-2 antibodies in people with an acute loss in their sense of smell and/or taste in a community-based population in London, UK: an observational cohort study. PLoS Med 2020 Oct 1;17(10):e1003358. https://doi.org/10.1371/journal.pmed.1003358.
[18] Shigemura N, Takai S, Hirose F, Yoshida R, Sanematsu K, Ninomiya Y. Expression profile of olfactory receptors in COVID-19: preventive care and precautionary measures. Am J Otolaryngol 2020 Apr 19;42(6):103068. https://doi.org/10.1016/j.amjoto.2020.102581.
[19] Fantozzi PJ, Pampena E, Di Vanna D, Pellegrino E, Corbi D, Mammucari S, Alessi F, Pampena R, Bertazzoni G, Minisola S, Mastroianni CM, Polimeni A, Romeo U, deichs, PC, Vandenbroucke JP. The impact of COVID-19 on olfactory and gustatory functions. Microorganisms 2020;8(7):97.
[20] Mehta P, McCullough AJ,örü, C, et al. COVID-19: new onset anosmia during the covid-19 pandemic. Rhinology 2020;58(3):295–9.
[38] Lechier JR, Chiesa-Estomba CM, Vaira LA, De Riu G, Cammaroto G, Chekkoury-Idrissi Y, Circiu M, Distingugiu L, Journe F, de Terwagne C, Machayekhi S, Barilari MB, Calvo-Henriquez C, Hans S, Sausee S. Epidemiological, otorhinolaryngological, olfactory and gustatory outcomes according to the severity of COVID-19: a study of 2579 patients. Eur Arch Otorhinolaryngol 2021 Jan;161:1-9. https://doi.org/10.1007/s00405-020-08548-w.

[39] Kaye E, Chang CWD, Kazahaya K, Berretton J, Demnery JC. COVID-19 anosmia reporting tool: initial findings. Otolaryngol Head Neck Surg 2020;163(1):132-4.

[40] D’Ascanio L, Pandolfini M, Cingolani L, Latini G, Gradosi P, Capalbo M, Frusinir G, Maranzano M, Brenner MJ, Di Stadio A. Olfactory dysfunction in COVID-19 patients: prevalence and prognosis for recovering sense of smell. Otolaryngol Head Neck Surg 2021 Jan;164(1):82-6. https://doi.org/10.1177/0194599820943530.

[41] Fuccillo E, Saibene AM, Canevini MP, Felisati G. Olfactory disorders in coronavirus disease 2019 patients: a systematic literature review. J Laryngol Otol 2020 Sep;15:1-10. https://doi.org/10.1017/s0022215120002005.

[42] Santos REA, da Silva MG, do Monte Silva MCB Gomes ALDV Barbosa DAM. Onset and duration of symptoms of loss of smell/taste in patients with COVID-19: a systematic review. Am J Otolaryngol 2021 Mar-Apr;42(2):102889. https://doi.org/10.1016/j.amjoto.2020.102889.

[43] Boscolo-Rizzo P, Borsetto D, Fabbris C, et al. Evolution of altered sense of smell or taste in patients with mildly symptomatic COVID-19. JAMA Otolaryngol Head Neck Surg 2020;146(8):729-32.

[44] Speth MM, Singer-Cornelius T, Oberle M, Gengler I, Brockmeier SJ, Sedaghat AR. Time scale for resolution of olfactory dysfunction in COVID-19. Rhinol J 2020;58:404-5.

[45] Pudero A, Mattaveli D, Rampinelli V, et al. Olfactory and gustatory outcomes in COVID-19: a prospective evaluation in nonhospitized subjects. Otolaryngol Head Neck Surg 2020;163(6):1144-9.

[46] Amer MA, Elshteri HS, Abdel-Hamid AS, Elzayat S. Early recovery patterns of olfactory disorders in COVID-19 patients: a clinical cohort study. Am J Otolaryngol 2020 Nov-Dec;41(6):102625. https://doi.org/10.1016/j.amjoto.2020.102625.

[47] Biadsee A, Dagan O, Ormianer Z, Kassem F, Masarwa S, Biadsee A. Eight-month follow-up of olfactory and gustatory dysfunction in recovered COVID-19 patients. Am J Otolaryngol 2021 Jul-Aug;42(4):103065. https://doi.org/10.1016/j.amjoto.2021.103065.

[48] Freni F, Meduri A, Gazia F, Nicoastro V, Galletti C, Aragona P, Galletti C, C Galletti B, Galletti B, Galletti F. Symptoms and duration of symptoms of loss of smell/taste in patients with COVID-19: a possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol 2020 Sep-Oct;41(5):102612. https://doi.org/10.1016/j.amjoto.2020.102612.

[49] Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kursuvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020;77(8):1018-27.

[50] Renaud M, Leon A, Trau G, et al. Acute smell and taste loss in outpatients with COVID-19: a prospective study. J Infect 2020;81(5):816.

[51] Vaira LA, Lechier JR, De Riu G, Sausee S. Chemosensory dysfunction in COVID-19: is there really a correlation with viral load? Am J Otolaryngol 2021 Jul-Aug;42(4):103027. https://doi.org/10.1016/j.amjoto.2021.103027.

[52] Cho RH, To ZWH, Yeung ZWC, Tso EYK, Fung KSC, Chau SKY. COVID-19 viral load in the severity of and recovery from olfactory and gustatory dysfunction. Laryngoscope 2020;130:2460-5.

[53] Jain A, Pandey AK, Kaur J, Kumar L, Singh M, Das S, Purohit S. Is there a correlation between viral load and olfactory & taste dysfunction in COVID-19 patients? Am J Otolaryngol 2021 May-Jun;42(3):102911. https://doi.org/10.1016/j.amjoto.2021.102911.

[54] Naeini AS, Karimi-Galougahi M, Raad N, Ghorbani J, Taraghi A, Haseli S, Mehrparvar G, Bakhsheyskharam M. Paranasal sinus computed tomography findings in anosmia of COVID-19. Am J Otolaryngol 2020 Nov-Dec;41(6):102636. https://doi.org/10.1016/j.amjoto.2020.102636.

[55] Tuasonelli C, Mocojli F, Baldani F, Bruno R, Benazzo M. COVID-19: what if the brain had a role in causing the death? Eur J Neurol 2020;27(9):e41-2.

[56] Gorkowski V, Bevilacqua S, Charmillon A, et al. Evolution of olfactory disorders in COVID-19 patients. Laryngoscope 2020;130(11):2667-73.

[57] Frini F, Meduri A, Gazia F, Nicoastro V, Galletti C, Aragona P, Galletti C, Galletti B, Galletti F. Symptoms and duration of symptoms of loss of smell/taste in patients with COVID-19: a possible neuroinvasive action of SARS-CoV-2. Am J Otolaryngol 2020 Sep-Oct;41(5):102612. https://doi.org/10.1016/j.amjoto.2020.102612.

[58] Zubair AS, McAlpine LS, Gardin T, Farhadian S, Kursuvilla DE, Spudich S. Neuropathogenesis and neurologic manifestations of the coronaviruses in the age of coronavirus disease 2019: a review. JAMA Neurol 2020;77(8):1018-27.

[59] Cho RH, To ZWH, Yeung ZWC, Tso EYK, Fung KSC, Chau SKY. COVID-19 viral load in the severity of and recovery from olfactory and gustatory dysfunction. Laryngoscope 2020;130:2460-5.

[60] Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging alteration of the olfactory system in patients infected with SARS-CoV-2? Rhinology 2020;58:406-9.

[61] Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 2020;6(31):eabc5801.

[62] Chetrit A, Lechien JR, Ammar A, et al. Magnetic resonance imaging of COVID-19 anosmia in a patient with COVID-19. Eur Radiol 2020;30(9):5115-9.

[63] Morbini P, Benazzo M, Verga L, et al. Ultrastructural evidence of direct viral damage to the olfactory complex in patients testing positive for SARS-CoV-2. J Neuropathol Exp Neurol 2020 Sep-Oct;79(8):1028.

[64] Bilinska K, Jakubowska P, Von Bartheld CS, Butowt R. Expression of the SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 2020;6(31):eabc5801.

[65] Brahn DH, Tsukahara T, Weinreb E, et al. Non-neuronal expression of SARS-CoV-2 entry genes in the olfactory system suggests mechanisms underlying COVID-19-associated anosmia. Sci Adv 2020;6(31):eabc5801.

[66] Paranasal sinuses computed tomography findings in anosmia of COVID-19. Am J Otolaryngol 2020 Nov-Dec;41(6):102636. https://doi.org/10.1016/j.amjoto.2020.102636.

[67] Politi LS, Salsano E, Grimaldi M. Magnetic resonance imaging of the brain in a patient with coronavirus disease 2019 (COVID-19) and anosmia. J Neurol 2020;277(8):1028-9.

[68] Cho RH, To ZWH, Yeung ZWC, Tso EYK, Fung KSC, Chau SKY. COVID-19 viral load in the severity of and recovery from olfactory and gustatory dysfunction. Laryngoscope 2020;130:2460-5.

[69] Chen J, Lechien JR, Ammr A, et al. Magnetic resonance imaging of COVID-19 anosmia. J Neurol 2020;277(8):1028-9.

[70] Panagi A, Zervas T, Laskarzewski M, et al. Magnetic resonance imaging of COVID-19 anosmia in a patient with COVID-19. Eur Radiol 2020;30(9):5115-9.